QTREX Posts Record H1 Revenue of $1.55M, Up 438%, but Flags Going Concern Doubt
QTEX has more than doubled off its 52-week low of $0.283.
Summary
QTREX Quantum reported record first half 2026 revenue of $1.55 million, up 438%, driven entirely by its newly acquired AME business, but disclosed substantial doubt about its ability to continue as a going concern.
Key Events · Earnings and Guidance · QTEX
-
Record H1 Revenue of $1.55M
First half 2026 revenue reached $1.55 million, up 438% from $289,000 in H1 2025, at a 61% gross margin. All revenue came from the AME and Quantum segment in its first 86 days after the April 6, 2026 acquisition.
-
Going Concern Doubt Disclosed
The company states its dependency on external funding for operations raises substantial doubt about its ability to continue as a going concern. Accumulated losses total $86 million as of June 30, 2026.
-
Net Loss of $6.4M
Consolidated net loss was $6.4 million, or $0.14 per share, compared with $6.4 million, or $0.24 per share, in H1 2025. The medical technology segment accounted for $5.5 million of the $6.9 million operating loss.
-
Cash Position of $10.7M
Cash, cash equivalents and deposits totaled $10.7 million at June 30, 2026, up from $3.2 million at December 31, 2025. The August 20, 2026 registered direct offering added approximately $9.2 million net, not included in the June 30 balance.
Analysis · QTEX · Industrial Applications And Services
The first half of 2026 delivered explosive revenue growth for QTREX Quantum, driven entirely by its newly acquired AME business—$1.55 million, up 438% year-over-year at a 61% gross margin. Yet the same report discloses substantial doubt about the company's ability to continue as a going concern. The AME segment generated all revenue in its first 86 days under QTREX, while the legacy medical technology segment produced zero revenue and accounted for $5.5 million of the $6.9 million operating loss. Cash of $10.7 million at June 30, 2026, plus the $9.2 million net raised in the August 20 registered direct offering, provides runway, but the company's own disclosure states dependency on external funding raises substantial doubt about its ability to continue. The INSU300 launch and validation deployments at two government and defense organizations represent early commercial traction, but the company has not yet converted these into recurring revenue. The Q4 2026 commercial agreement announcements and 2027 financial outlook are the next concrete milestones.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1052 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QTEX was trading at $0.76 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $51M. The 52-week trading range was $0.28 to $3.85. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.